US › Healthcare

PepGen Ltd (PEPG)

US · Healthcare · Biotechnology

$1.93+2.66%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-17.8M

Profit YoY

+41.2%

EPS

$-0.26

EPS estimate

$-0.35

EPS came in at -0.26 against a street estimate of -0.35 — a beat of 26.0%.

Key statistics

Market cap

$121.7M

Forward P/E

0.0

P/B

0.91

Book value

$1.94

EPS (TTM)

$-1.46

52-week high

$7.80

52-week low

$1.01

50-day MA

$1.78

200-day MA

$3.88

Beta

1.89

Analyst view

Analysts rate PepGen Ltd a buy (4 buy, 0 hold, 1 sell out of 5) with an average price target of $10.25.

Shareholding

Insiders

0.23%

Institutions

86.47%

Largest institutional holders

Fund	Stake
RA Capital Management, LLC	29.01%
COMMODORE CAPITAL LP	6.47%
Viking Global Investors LP	5.03%
LAURION CAPITAL MANAGEMENT LP	3.98%
Vivo Capital, LLC	3.36%
Millennium Management LLC	3.01%
Vanguard Capital Management, LLC	2.80%
Awm Investment Company Inc	2.65%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for PepGen Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.